As one of the budget management units of the National Health and Family Planning Commission (formerly the Ministry of Health) and of Shanghai Red Cross hospitals, Fudan University Shanghai Cancer Center (FUSCC) is a grade-A tertiary hospital, engaged in clinical practice, medical education, oncological research and cancer prevention. Historically, it can be traced back to Sino-Belgian Radium Institute established on March 1, 1931 as the earliest special hospital of oncology in China.
As of 2015, FUSCC is staffed with 1,851 medical workers, including 218 full and associate professors (52 MD and 75 MS mentors), 473 physicians and surgeons, 793 nurses, and 382 medical technicians. Prof. LIU Taifu holds honorably the title of Academician, American College of Radiology and Honorable Fellow, European Society of Radiology; and Prof. JIANG Guoliang, the title of Academician, American College of Radiology.
In discipline, FUSCC is made up of Department of Head & Neck Surgery, Department of Breast Surgery, Department of Thoracic Surgery, Department of Gastric Cancer and Soft Tissue Sarcomas, Department of Colorectal Surgery, Department of Urology, Department of Pancreatic Surgery, Department of Hepatic Surgery, Department of Brain & Spine Surgery, Department of Gynecologic Oncology, Department of Medical Oncology, Department of Radiation Oncology, Department of Traditional Chinese Medicine/Integrative Oncology, Department of Comprehensive Treatment, Department of Interventional Radiology, Department of Anesthesiology, Department of Clinical Laboratory, Department of Blood Transfusion, Department of Pharmacy, Department of Endoscope, Department of Pathology, Department of Ultrasound, Department of Radiology, Department of Pulmonary Function, Department of Nuclear Medicine, Department of Clinical Nutriology.
FUSCC, designed to offer 800 sick beds, actually has 1,234 in operation. The year of 2015 witnessed 1,213,000 outpatient visits including those of emergency, 56,400 hospitalizations with average stay length of 7.8 days and 34,400 surgeries, which topped the counterparts across the country.
In 2015, FUSCC enrolled 47 MS candidates, 38 MD candidates and 2 post-doctors, and meanwhile turned out 34 MS and 43 MD graduates. A total number of 147 MS and 140 MD students were being trained, together with 4 post-doctors.
As to scientific research, a total number of 159 research projects were won in the accumulative total amount of RMB69,840,000.00, including 49 funded by the Natural Science Foundation of China (RMB17,140,000.00), out of which were published 328 SCI papers (1359 IFs in total), 85 of them individually accounting for 5 and over 5 IFs (e.g. Nature, Lancet Oncology, JCO). Additionally, FUSCC was authorized 12 patents, 6 for invention and 6 for utility model.
At present, oncology and clinical pathology are highly recognized as the key academic discipline by the Ministry of Education; Pathology, Integration of Traditional and Western Medicine as well as Oncology, as the state key clinical specialties; and Breast Cancer Oncology, Radiotherapy and Pathology, as the key clinical disciplines by the Ministry of Health. In Shanghai, FUSCC is authorized to have key discipline of clinical pathology (Type A) and also to have key discipline of clinical medicine (Type B). FUSCC serves as the Center for Pathological QC, the Center for Radiotherapeutic QC, and the Center for Chemotherapeutic QC, respectively. To FUSCC is also attached Shanghai Anti-cancer Association.
In addition, FUSCC is equipped with such institutes as National Drug Clinical Trials authorized by State Food and Drug Administration, Key Laboratory on Breast Cancer in Shanghai, Molecular Imaging Probe Engineering and Technological Research Center in Shanghai, Fudan University Cancer Research Institute, Fudan University Pathology Institute, Institute on Breast Cancer of Fudan University, Institute on Pancreatic Cancer of Fudan University, Research Center on Colorectal Cancer of Fudan University; Research Center on Nasopharyngeal Carcinoma of Fudan University; Research Center on Prostate Cancer of Fudan University, Research Center on Thyroid Cancer of Fudan University, Lung Cancer Prevention & Treatment Research Center of Fudan University, Biomedical Imaging Research Center of Fudan University, and Malignant Melanoma Prevention & Treatment Research Center of Fudan University.
FUSCC is in charge of China Oncology, Oncoradiology, Journal of Radiation Oncology (in English), and Anticancer (for the populations in general).
While maintaining a deep commitment to the basic mission to care for the patient, FUSCC is dedicated to building collaborative partnerships and cherishing its influential image. As a result of such efforts, great progresses have been made in total quality improvement and overall patient satisfaction. Based on the well established partnerships with the branches in Minhang District of Shanghai and Taizhou City of Zhejiang Province, FUSCC initiated the partnership with Suzhou Science & Technology City Hospital, the 2nd People’s Hospital in Wuhu City and Zhangjiagang AoYoung Hospital, respectively, in 2015 to spread its quality medical services. Internationally, FUSCC has established sister-institution programs with MD Anderson Cancer Center at Texas in USA; The Cancer Center, Singapore National Health Group, Singapore National University; Institut Gustave Roussy in France; Cancer Research Institute of Kanazawa University, Japan; European Institute of Oncology, Italy; and DUKE Cancer Institute, USA, for the purpose of promoting international collaborations and exchanges in research, training and referral, advancing the construction of its own disciplines and improving its academic prestige in the world.
In building professionalism as required by the furthered medical reforms, a series of activities on rigorous self-discipline and honest self-behavior have been carried out among CPC members and managerial leaders at FUSCC so that the management paradigm and the environment of medical practice are improved in every detail towards total quality improvement and overall patient satisfaction. As an illustration of this in 2015, PDCA programs were conducted across FUSCC to sustain the improvement of quality; the staffs were actively involved in the standardized management and performance evaluation.
On May 8, 2015, Shanghai Proton and Heavy Ion Center or Proton and Heavy Ion Center of Fudan University Shanghai Cancer Center came officially into operation with the registration of the system facilities and authorized documents, the historical unveiling joined by Party Secretary HAN Zheng of the city government. Since then, the center has been operated smoothly thanks to the well-established rules and regulations, and more importantly, the therapeutic edge has been manifested based on an accumulation of clinical treatment experience. Apparently, the center will benefit a growing number of patients.
FUSCC, which is well-staffed, well-equipped, well-skilled and well-managed, is deeply committed to providing patients with quality medical services in the palatable and comfortable treating environment.